Acerta Pharma

Michael Yee of RBC Capital Markets commented in a note that M&A activity within small- and mid-cap healthcare companies "doesn't seem to be slowing down much." Yee added that "good" late-stage and de-risked drugs should command a high value, regardless of any political uncertainty. The latest...